title: Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial.
abstract: BACKGROUND
  The risk-benefit ratio of invasive vs medical management of elderly patients with symptomatic chronic coronary artery disease (CAD) is unclear. The Trial of Invasive versus Medical therapy in Elderly patients (TIME) recently showed early benefits in quality of life from invasive therapy in patients aged 75 years or older, although with a certain excess in mortality.
  
  
  OBJECTIVE
  To assess the long-term value of invasive vs medical management of chronic CAD in elderly adults in terms of quality of life and prevention of major adverse cardiac events.
  
  
  METHODS
  One-year follow-up analysis of TIME, a prospective randomized trial with enrollment between February 1996 and November 2000.
  
  
  METHODS
  A total of 282 patients with Canadian Cardiac Society class 2 or higher angina despite treatment with 2 or more anti-anginal drugs who survived for the first 6 months after enrollment in TIME (mean age, 80 years [range, 75-91 years]; 42% women), enrolled at 14 centers in Switzerland.
  
  
  METHODS
  Participants were randomly assigned to undergo coronary angiography followed by revascularization (if feasible) (n = 140 surviving 6 months) or to receive optimized medical therapy (n = 142 surviving 6 months).
  
  
  METHODS
  Quality of life, assessed by standardized questionnaire; major adverse cardiac events (death, nonfatal myocardial infarction, or hospitalization for acute coronary syndrome) after 1 year.
  
  
  RESULTS
  After 1 year, improvements in angina and quality of life persisted for both therapies compared with baseline, but the early difference favoring invasive therapy disappeared. Among invasive therapy patients, later hospitalization with revascularization was much less likely (10% vs 46%; hazard ratio [HR], 0.19; 95% confidence interval [CI], 0.11-0.32; P<.001). However, 1-year mortality (11.1% for invasive; 8.1% for medical; HR, 1.51; 95% CI, 0.72-3.16; P =.28) and death or nonfatal myocardial infarction rates (17.0% for invasive; 19.6% for medical; HR, 0.90; 95% CI, 0.53-1.53; P =.71) were not significantly different. Overall major adverse cardiac event rates were higher for medical patients after 6 months (49.3% vs 19.0% for invasive; P<.001), a difference which increased to 64.2% vs 25.5% after 12 months (P<.001).
  
  
  CONCLUSIONS
  In contrast with differences in early results, 1-year outcomes in elderly patients with chronic angina are similar with regard to symptoms, quality of life, and death or nonfatal infarction with invasive vs optimized medical strategies based on this intention-to-treat analysis. The invasive approach carries an early intervention risk, while medical management poses an almost 50% chance of later hospitalization and revascularization.
authors.affiliation: Department of Cardiology, University Hospital, Petersgraben 4, CH-4031 Basel, Switzerland. pfisterer@email.ch
authors.forename: Matthias
authors.initials: M
authors.lastname: Pfisterer
authors.forename: Peter
authors.initials: P
authors.lastname: Buser
authors.forename: Stefan
authors.initials: S
authors.lastname: Osswald
authors.forename: Urs
authors.initials: U
authors.lastname: Allemann
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Amann
authors.forename: Walter
authors.initials: W
authors.lastname: Angehrn
authors.forename: Eric
authors.initials: E
authors.lastname: Eeckhout
authors.forename: Paul
authors.initials: P
authors.lastname: Erne
authors.forename: Werner
authors.initials: W
authors.lastname: Estlinbaum
authors.forename: Gabriela
authors.initials: G
authors.lastname: Kuster
authors.forename: Tiziano
authors.initials: T
authors.lastname: Moccetti
authors.forename: Barbara
authors.initials: B
authors.lastname: Naegeli
authors.forename: Peter
authors.initials: P
authors.lastname: Rickenbacher
mesh_terms: D000368:Aged; D000787:Angina Pectoris / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D006328:Cardiac Catheterization; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000401:mortality / Q000601:surgery / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009204:Myocardial Revascularization; D011788:Quality of Life; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents